This OncLive Insights program brings together Dr. Hans Lee, Dr. Muhamed Baljevic, and Dr. Prashant Kapoor to discuss the rapidly evolving treatment landscape in multiple myeloma and its implications for clinical practice. The panel examines how advances in quadruplet regimens, CAR T-cell therapy, bispecific antibodies, and emerging immune-based approaches are reshaping treatment strategies across newly diagnosed and relapsed/refractory multiple myeloma. The discussion explores treatment sequencing, continuous versus fixed-duration therapy, de-escalation, MRD-guided decision-making, and the balance between disease control, treatment-related toxicity, quality of life, and patient preferences. The experts also address supportive care and strategies to mitigate infections and cytokine release syndrome, approaches to improving access to T-cell-engaging therapies in community settings, and considerations for sequencing therapies after BCMA-directed treatment. Looking ahead, the panel considers emerging targets, trispecific antibodies, in vivo CAR T-cell approaches, CELMoDs, and other developments that may further transform multiple myeloma management.
In this segment, Dr. Hans Lee introduces the rapidly evolving treatment landscape in multiple myeloma and outlines how advances in immunotherapy, quadruplet regimens, CAR T-cell therapy, and bispecific antibodies are reshaping management across newly diagnosed and relapsed disease.
In this segment, Dr. Hans Lee and Dr. Muhamed Baljevic discuss treatment goals and evolving frontline strategies for multiple myeloma, with an emphasis on balancing disease control with long-term quality of life.
